Venus Remedies Limited has informed the Exchange regarding 'US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies VRP-034, a Novel Polymyxin B Formulation'.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies has received Qualified Infectious Disease Product (QIDP) designation from the US FDA for VRP-034, its novel Polymyxin B formulation. Polymyxin B is an antibiotic used to treat serious multi-drug resistant infections. QIDP status, awarded under the US GAIN Act, brings benefits like priority review, faster approval pathway, and an additional 5 years of market exclusivity if approved. The designation strengthens Venus Remedies' position in the critical antibiotics space and could accelerate its entry into the US pharmaceutical market. No financial figures or timelines for commercial launch were disclosed in this filing.
Positive for long-term prospects — QIDP designation de-risks the US regulatory path and adds exclusivity, but no immediate revenue impact since the drug still needs to complete clinical trials and secure final FDA approval.